Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 5, 2005, Pages 1932-1942

  Kosowska, Klaudia ^a   Hoellman, Dianne B ^a   Lin, Gengrong ^a   Clark, Catherine ^a   Credito, Kim ^a   McGhee, Pamela ^a   Dewasse, Bonifacio ^a   Bozdogan, Bülent ^a   Shapiro, Stuart ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFDINIR; CEFEPIME; CEFOTAXIME; CEFTOBIPROLE; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; IMIPENEM; LINEZOLID; MACROLIDE; PENICILLIN DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TELITHROMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM MUTANT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCUS PNEUMONIAE;

EID: 20944431809     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.5.1932-1942.2005     Document Type: Article

References (58)

1. Appelbaum, P. C. 1992, Antimicrobial resistance in Streptococcus pneumoniae - an overview. Clin. Infect. Dis. 15:77-83.
2. Azoulay-Dupuis, E., J. P. Bédos, J. Mohler, A. Schmitt-Hoffmann, M. Schleimer, and S. Shapiro. 2004. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother, 48:1105-1111.
3. Block, S., C. J. Harrison, J. A. Hedrick, R. D. Tyler, R. A. Smith, E. Keegan, and S. A. Chartrand. 1995. Penicillin-resistant Streptococcus pneumonias in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Pediatr. Infect. Dis. J. 14:751-759.
4. Bozdogan, B., and P. C. Appelbaum. 2004. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents 23:113-119.
5. Breiman, R. F., J. C. Butler, F. C. Tenover, J. A. Elliott, and R. R. Facklam. 1994. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 271:1831-1835.
6. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
7. Browne, F. A., B. Bozdogan, C. Clark, L. M. Kelly, L. Ednie, K. Kosowska, B. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 2003. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents. Antimicrob. Agents Chemother. 47:3815-3824.
8. Canu, A., B. Malbruny, M. Coquemont, T. A. Davies, P. C. Appelbaum, and R. Leclercq. 2002. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:125-131.
9. Davies, T. A., B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 2000. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:414-417.
10. Davies, T. A., L. M. Kelly, G. A. Pankuch, K. L. Credito, M. R. Jacobs, and P. C. Appelbaum. 2000. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob. Agents Chemother. 44: 304-310.
11. Davies, T. A., G. A. Pankuch, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 1999. In vitro development of resistance to five quinolones and amoxicillin/clavulanate in Streptococcus pneumonias. Antimicrob. Agents Chemother. 43:1177-1182.
12. Depardieu, F., and P. Courvalin. 2001. Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:319-323.
13. Deshpande, L. M., and R. N. Jones. 2003. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. 9:1120-1124.
14. Farrell, D. J., S. G. Jenkins, and R. R. Reinert. 2004. Global distribution of Streptococcus pneumoniae serotypes isolated from paediatric patients during 1999-2000 and the in vitro efficacy of telithromycin and comparators. J. Med. Microbiol. 53:1109-1117.
15. Friedland, I. R., and G. S. Istre. 1992. Management of penicillin-resistant pneumococcal infections. Pediatr. Infect. Dis. J. 11:433-435.
16. Friedland, I. R., and G. H. McCracken, Jr. 1994. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J. Med. 331:377-382.
17. Haight, T. H., and M. Finland. 1952. Resistance of bacteria to erythromycin. Proc. Soc. Exp. Biol. Med. 81:183-188.
18. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. P. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
19. Ho, P.-L., T.-L. Que, S. S. Chiu, R. W. H. Yung, T.-K. Ng, D. N. C. Tsang, W.-H. Seto, and Y.-L. Lau. 2004. Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong. 1995-2001. Emerg. Infect. Dis. 10:1250-1257.
20. Issa, N. C., M. S. Rouse, K. E. Piper, W. R. Wilson, J. M. Steckelberg, and R. Patel. 2004. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 48:73-75.
21. Jacobs, M. R. 1992. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 15:119-127.
22. Jacobs, M. R., and P. C. Appelbaum. 1995. Antibiotic-resistant pneumococci. Rev. Med. Microbiol. 6:77-93.
23. Jacobs, M. R., S. Bajaksouzian, A. Zilles, G. Lin, G. A. Pankuch, and P. C. Appelbaum. 1999. Susceptibilities of Streptococcus pneumoniae and Haemophilus infiuenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study. Antimicrob. Agents Chemother. 43:1901-1908.
24. Jacobs, M. R., S. Bajaksouzian, and P. C. Appelbaum. 2003. Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 gram-positive cocci. J. Antimicrob. Chemother. 52:809-812.
25. Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenbach. 2002. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50:915-932.
26. Kresken, M., M. Heep, and I. Wiegand. 2004. Gram-negative bacteria producing beta-lactamases: in vitro activities of BAL 9141 and comparators. Clin. Microbiol. Infect. 10(Suppl. 3):120-121.
27. Kresken, M., and M. Heep. 2004. In vitro activities of BAL9141 and seven other beta-lactam antimicrobial agents towards clinical isolates of 12 members of the Enterobacteriaceae. Clin. Microbiol. Infect. 10(Suppl. 3):334.
28. Laganas, V., J. Alder, and J. A. Silverman. 2003. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob. Agents Chemother. 47:2682-2684.
29. Liñares, J., A. G. Campa, and R. Pallares. 1999. Fluoroquinolone-resistance in Streptococcus pneumoniae. N. Engl. J. Med. 20:1546-1548.
30. Livermore, D. M. 2003. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51(Suppl. 2):ii9-ii16.
31. McCullers, J. A., B. K. English, and R. Novak. 2000. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cevebrospinal fluid of a patient who developed recrudescent meningitis. J. Infect. Dis. 181:369-373.
32. McDougal, L. K., R. Facklam, M. Reeves, S. Hunter, J. M. Swenson, B. C. Hill, and F. C. Tenover. 1992. Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob. Agents Chemother. 36:2176-2184.
33. Muñoz, R., J. M. Musser, M. Crain, D. E. Briles, A. Marton, A. J. Parkinson, U. Sorensen, and A. Tomasz. 1992. Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin. Infect. Dis. 15:112-118.
34. Nagai, K., T. A. Davies, G. A. Pankuch, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 2000. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2740-2746.
35. Nagai, K., P. C. Appelbaum, T. A. Davies, L. M. Kelly, D. B. Hoellman, A. T. Andrasevic, L. Drukalska, W. Hryniewicz, M. R. Jacobs, J. Kolman, J. Miculeviciene, M. Pana, L. Setchanova, M. K. Thege, H. Hupkova, J. Trupl, and P. Urbaskova. 2002. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 Central and Eastern European countries. Antimicrob. Agents Chemother. 46:371-377.
36. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
37. National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing-13th informational supplement. M100-S14. National Committee for Clinical Laboratory Standards, Wayne, Pa.
38. Pan, X. S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
39. Pankuch, G. A., B. Bozdogan, K. Nagai, A. Tambić- Andrašević, S. Schoenwald, T. Tambić, S. Kalenić, S. Pleško, N. K. Tepeš, Z. Kotarski, M. Payerl-Pal, and P. C. Appelbaum. 2002. Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia. Antimicrob. Agents Chemother. 46:2671-2675.
40. Pankuch, G. A., T. A. Davies, M. R. Jacobs, and P. C. Appelbaum. 2002. Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents. Antimicrob. Agents Chemother. 46:42-46.
41. Pankuch, G. A., S. A. Juenemann, T. A. Davies, M. R. Jacobs, and P. C. Appelbaum. 1998. In vitro selection of resistance to four β-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2914-2918.
42. Pankuch, G. A., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1998. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647). a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob. Agents Chemother. 42:624-630.
43. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1995. Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. J. Antimicrob. Chemother. 35:883-888.
44. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1994. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob. Agents Chemother. 38:2065-2072.
45. Powis, J., A. McGeer, K. Green, O. Vanderkooi, K. Weiss, G. Zhanel, T. Mazzulli, M. Kuhn, D. Church, R. Davidson, K. Forward, D. Hoban, A. Simor, D. E. Low, and the Canadian Bacterial Surveillance Network. 2004. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob. Agents Chemother. 48: 3305-3311.
46. Reinert, R. R., A. Wild, P. Appelbaum, R. Lütticken, M. Y. Cil, and A. Al-Lahham. 2003. Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany. Antimicrob. Agents Chemother. 47:2319-2322.
47. Rosato, A., H. Vicarini, and R. Leclercq. 1999. Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin. J. Antimicrob. Chemother. 43:559-562.
48. Schito, A. M., G. C. Schito, E. Debbia, G. Russo, J. Linares, E. Cercenado, and E. J. Bouza. 2003. Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999-2000. J. Chemother. 15:226-234.
49. Schmitt-Hoffmann, A., B. Roos, M. Schleimer, J. Sauer, A. Man, N. Nashed, T. Brown, A. Perez, E. Weidekamm, and P. Kovács. 2004. Single-dose pharmacokinetcis and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48:2570-2575.
50. Schmitt-Hoffmann, A., L. Nyman, B. Roos, M. Schleimer, J. Sauer, N. Nashed, T. Brown, A. Man, and E. Weidekamm. 2004. Multiple-dose pharmacokinetics and safety of a broad-spectrum cephalosporin (BAL5788) on healthy volunteers. Antimicrob. Agents Chemother. 48:2576-2580.
51. Schmitt-Hoffmann, A. H., B. Roos, M. Keep, M. Schleimer, E. Weidekamm, A. Man, and N. Abdou. 2004. Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of prodrug BAL5788. Clin. Microbiol. Infect. 10(Suppl. 3):276-277.
52. Schmitt-Hoffmann, A. H., M. Harsch, M. Keep, M. Schleimer, T. Brown, A. Man, and W. O'Riordan. 2004. BAL5788 in patients with complicated skin and skin structure infections caused by gram-positive pathogens including methicillin-resistant Staphylococcus species. Interim pharmacokinetic results from 20 patients. Clin. Microbiol. Infect. 10(Suppl. 3):277.
53. Schmitt-Hoffmann, A. H., B. Roos, M. Schleimer, E. Weidekamm, T. Brown, M. Heep, A. Man, and L. G. Nilsson. 2004. Dose adjustment in subjects with normal and impaired renal function based on the pharmacokinetics of BAL5788. Clin. Microbiol. Infect. 10(Suppl. 3):277.
54. Spangler, S. K., M. R. Jacobs, G. A. Pankuch, and P. C. Appelbaum. 1993. Susceptibility of 170 penicillin-susceptible and -resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. J. Antimicrob. Chemother. 31:273-280.
55. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.
56. Visalli, M. A, M. R. Jacobs, and P. C. Appelbaum. 1996. MIC and time-kill study of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 40:362-366.
57. Walsh, F., J. Willcock, and S. Amyes. 2003. High-level resistance in laboratory-generated mutants of Streptococcus pneumoniae. J. Antimicrob. Chemother. 52:345-353.
58. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40:839-845.